Industry News

Since the rise of accumulator and maximizer programs, many stakeholders within the pharmacy industry have been looking to tip the scales back towards traditional copay assistance models.

By understanding your contract, communicating with your PBM, and working with a partner to craft your pharmacy strategy, you’ll be well prepared for the rise of biosimilar drugs.

On May 17, 2022, the U.S. District Court for DC ruled against the “accumulator adjustment rule.” What impact will this have on pharma?

6,000 pharmacy professionals attended Asembia this year. What were the key takeaways from the conference?

Four core themes from Asembia 2021 that will drive dialogue in the specialty pharmacy ecosystem in 2022 – and beyond.

Read Truveris’ data report on the impact of COVID-19 on pharma, specifically prescribing and claims numbers for branded drugs.

What is the future of the PBM landscape? Listen to Truveris CEO, Nanette Oddo, opine on the shifts she’s seeing in the pharmacy ecosystem.

Truveris announced today that Nanette Oddo, formerly Truveris’ Chief Strategy Officer, has been named President and Chief Executive Officer.

Several states have passed legislation that prohibits the use of copay accumulator adjustment programs. How does this affect your organization?

In October of 2017, Anthem Inc. announced its launching of IngenioRx, an in-house pharmacy benefits manager (PBM).